SCHEMBL29392605

SCHEMBL29392605

Cc1nc(Cl)ccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 1/20 0.51
MAPT P10636 4/20 0.47
TXNRD1 Q16881 4/20 0.47
GSR P00390 3/20 0.47
TDP1 Q9NUW8 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
TSHR P16473 2/20 0.44
CYP3A4 P08684 1/20 0.44
HTT P42858 1/20 0.43
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.41
CTSB P07858 1/20 0.40
CTSH P09668 1/20 0.40
GAA P10253 1/20 0.40
FGFR4 P22455 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL381701 1.00 MERTK (0.51) MERTKMAPTTXNRD1GSRTDP1
SCHEMBL56616 0.83 MAPT (0.50) MERTKMAPTTXNRD1GSRTDP1
SCHEMBL29364858 0.83 MAPT (0.50) MERTKMAPTTXNRD1GSRTDP1
SCHEMBL5971901 0.80 ALDH1A1 (0.61) MERTKMAPTTXNRD1GSRTDP1
SCHEMBL30875970 0.80 NOS3 (0.48) MAPTTDP1L3MBTL1POLBTSHR
SCHEMBL539616 0.80 NOS3 (0.48) MAPTTDP1L3MBTL1POLBTSHR
SCHEMBL1128565 0.80 TSHR (0.44) MERTKMAPTTXNRD1TDP1L3MBTL1
SCHEMBL30810188 0.79 CTSB (0.54) MAPTTDP1L3MBTL1POLBTSHR
SCHEMBL1135629 0.79 CTSB (0.54) MAPTTDP1L3MBTL1POLBTSHR
SCHEMBL136263 0.78 CTSB (0.53) MERTKMAPTTDP1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215153-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2025-10-16 WO disclosed
EP-3953335-A1 INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS Cellestia Biotech AG (CH) 2022-02-16 EP disclosed